


(2'S,2''R)-4-(2'-(2''-(Carboxymethylamino)-3''-cyclohexylpropanoylamino)-3'-phenylpropanoylamino)piperidine-1-carboxamidinium trifluoroacetate



Applicant understands that once the elected species is determined to be patentable, the Examiner will examine the full scope of the elected claims.

The Restriction Requirement is based on an alleged lack of novelty the compounds recited in claim 1. In particular, the Restriction Requirement cited Griesbacher (November 2002) for teaching the compound labeled FE999026. Applicant respectfully points out that the cited reference is not prior art to the instant application, which was filed March 4, 2003 with a priority claim to March 8, 2002, which is several months prior to the publication of Greisbacher. As further evidence on this point, Applicant submits herewith a copy of the Table of Contents of the November 2002, issue of the British Journal of Pharmacology, listing the Greisbacher article.

Because all of the pending claims share a common special technical feature, the Restriction Requirement is improper and should be withdrawn.

Should there be any questions regarding this submission, or should any issues remain, the Examiner is invited to contact the undersigned at the telephone number set forth below.

Respectfully submitted,

Date May 7, 2008


FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 295-4094

Facsimile: (202) 672-5399

By



Courtenay C. Brinckerhoff

Attorney for Applicant

Registration No. 37,288

**The Commissioner is hereby authorized to charge any additional fees, which may be required regarding this application under 37 CFR §§ 1.16-1.17, and to credit any overpayment to Deposit Account No. 19-0741. Should no proper payment accompany this response, then the Commissioner is authorized to charge the unpaid amount to the same deposit account. If any extension is needed for timely acceptance of submitted papers, Applicants hereby petition for such extension under 37 CFR §1.136 and authorize payment of the related fee(s) from the deposit account.**



## TABLE OF CONTENTS

Volume 137, Issue 5 (November 2002)

[Commentary](#)[Review](#)[Papers](#)[Papers](#)

## COMMENTARY

**Cannabinoids throw up a conundrum FREE**

DeWayne Townsend IV, Stanley A Thayer and David R Brown

Br J Pharmacol 137: 575-577; doi:10.1038/sj.bjp.0704913

[Abstract](#) | [Full Text](#) | [PDF](#)[See also: Paper by Barann et al.](#)

## REVIEW

**Is urotensin-II the new endothelin? FREE**

Janet J Maguire and Anthony P Davenport

Br J Pharmacol 137: 579-588; doi:10.1038/sj.bjp.0704924

[Abstract](#) | [Full Text](#) | [PDF](#)

## PAPERS

**Direct inhibition by cannabinoids of human 5-HT<sub>3A</sub> receptors: probable involvement of an allosteric modulatory site FREE**

M Barann, G Molderings, M Brüss, H Bönnisch, B W Urban and M Göthert

Br J Pharmacol 137: 589-596; doi:10.1038/sj.bjp.0704829

[Abstract](#) | [Full Text](#) | [PDF](#)[See also: Commentary by Townsend et al.](#)

## PAPERS

**Extracellular zinc stimulates ERK-dependent activation of p21<sup>Cip/WAF1</sup> and inhibits proliferation of colorectal cancer cells FREE**

Ki-Sook Park, Yongho Ahn, Jin-Ah Kim, Mi-Sun Yun, Baik L Seong and Kang-Yell Choi

Br J Pharmacol 137: 597-607; doi:10.1038/sj.bjp.0704909

[Abstract](#) | [Full Text](#) | [PDF](#)**Molecular mechanisms of sulfasalazine-induced T-cell apoptosis FREE**

Susanne Liptay, Simone Fulda, Marta Schanbacher, Soizic Bourteele, Karine F Ferri, Guido Kroemer, Guido Adler, Klaus M Debatin and Roland M Schmid

Br J Pharmacol 137: 608-620; doi:10.1038/sj.bjp.0704870

[Abstract](#) | [Full Text](#) | [PDF](#)**Role of the platelet-activating factor (PAF) receptor during pulmonary infection with gram negative bacteria FREE**

A C Soares, V S Pinho, D G Souza, T Shimizu, S Ishii, J R Nicoli and M M Teixeira

Br J Pharmacol 137: 621-628; doi:10.1038/sj.bjp.0704918

[Abstract](#) | [Full Text](#) | [PDF](#)**A possible role of neurotensin in NANC relaxation of longitudinal muscle of the jejunum and ileum of Wistar rats FREE**

Michiru Yamaji, Mayuko Ohta, Yasuko Yamazaki, Kaori Fujinami, Akikazu Fujita, Tadayoshi Takeuchi, Fumiaki Hata and Tadashi Takewaki

Br J Pharmacol 137: 629-636; doi:10.1038/sj.bjp.0704914

[Abstract](#) | [Full Text](#) | [PDF](#)**Regional variation in P2 receptor expression in the rat pulmonary arterial circulation FREE**

K Chootip, K F Ness, Y Wang, A M Gurney and C Kennedy

Br J Pharmacol 137: 637-646; doi:10.1038/sj.bjp.0704915

[Abstract](#) | [Full Text](#) | [PDF](#)**The Na-K-ATPase is a target for an EDHF displaying characteristics similar to potassium ions in the porcine renal interlobar artery FREE**

Eckhart Büsselmaier, Christian Wallner, Beate Fisslthaler and Ingrid Fleming

Br J Pharmacol 137: 647-654; doi:10.1038/sj.bjp.0704919

[Abstract](#) | [Full Text](#) | [PDF](#)**The impairment of endothelium-dependent arterial relaxation by 7-ketocholesterol is associated with an early activation of protein kinase C FREE**

Valérie Deckert, Linda Duverneuil, Sandrine Poupon, Serge Monier, Naig Le Guern, Gérard Lizard, David Masson and Laurent Lagrost

Br J Pharmacol 137: 655-662; doi:10.1038/sj.bjp.0704920

[Abstract](#) | [Full Text](#) | [PDF](#)**Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1 $\beta$  FREE**

Chuan-Chu Chou, Jay S Fine, Catherine Pugliese-Sivo, Waldemar Gonsiorek, Liza Davies, Gregory Deno, Mary Petro, Martin Schwarz, Paul J Zavodny and R William Hipkin

Br J Pharmacol 137: 663-675; doi:10.1038/sj.bjp.0704907

[Abstract](#) | [Full Text](#) | [PDF](#)

**A novel  $\beta$ -sheet breaker, RS-0406, reverses amyloid  $\beta$ -induced cytotoxicity and impairment of long-term potentiation in vitro** FREE

Yasuhiro Nakagami, Satoko Nishimura, Takako Murasugi, Isao Kaneko, Masaki Meguro, Shinji Marumoto, Hiroshi Kogen, Kazuo Koyama and Tomiichiro Oda

Br J Pharmacol 137: 676-682; doi:10.1038/sj.bjp.0704911

[Abstract](#) | [Full Text](#) | [PDF](#)**Propofol prevents endothelial dysfunction induced by glucose overload** FREE

Yuji Karashima, Masahiro Oike, Shosuke Takahashi and Yushi Ito

Br J Pharmacol 137: 683-691; doi:10.1038/sj.bjp.0704912

[Abstract](#) | [Full Text](#) | [PDF](#)**Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats** FREE

Thomas Griesbacher, Irmgard Rainer, Beate Tiran and D Michael Evans

Br J Pharmacol 137: 692-700; doi:10.1038/sj.bjp.0704910

[Abstract](#) | [Full Text](#) | [PDF](#)**Pharmacological approach towards the development of indolequinone bio-reductive drugs based on the clinically inactive agent EO9** FREE

P M Loadman, M C Bibby and R M Phillips

Br J Pharmacol 137: 701-709; doi:10.1038/sj.bjp.0704916

[Abstract](#) | [Full Text](#) | [PDF](#)**Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin** FREE

Andrew R Kompa, Chrisan S Samuel and Roger J Summers

Br J Pharmacol 137: 710-718; doi:10.1038/sj.bjp.0704922

[Abstract](#) | [Full Text](#) | [PDF](#)**Calmodulin increases transmitter release by mobilizing quanta at the frog motor nerve terminal** FREE

Eugen Brailoiu, Michael D Miyamoto and Nae J Dun

Br J Pharmacol 137: 719-727; doi:10.1038/sj.bjp.0704923

[Abstract](#) | [Full Text](#) | [PDF](#)